Effect of tamoxifen treatment on the epidermal growth factor receptor expression in the mouse ovarian tissue

Yıl 2018, Cilt: 37 Sayı: 2, 119 - 125, 15.10.2018

Berrin Zık , Ender Deniz Asmaz

https://doi.org/10.30782/uluvfd.415592

Öz

The objective of
this study was to investigate the effect of Tamoxifen (TAM) treatment on
epidermal growth factor receptor (EGFR) expression in the pubertal mice ovary. In this study, 80 female mice (8 week-old) were used.
Animals divided four groups; non-injected (control A), injected with TAM’s
vehicle solution (control B). The mice in groups TAM 0.5 and TAM 1.5 were
treated with tamoxifen at a dose 0.5 and 1.5 mg/mouse/day respectively. TAM was
dissolved with 10% ethanol: 90% corn oil. Mice were
given daily subcutaneously injections for 5 days. Ovarian sections were
immunostained with EGFR antibody and triple staining for examine the general
structure. We observed that follicular atresia was increased, follicular cysts
were formed in stroma, and interstitial cells were increased with TAM dose
treatment. In the present study, there were no significant differences in the
EGFR expression in mouse ovary of all groups. EGFR expression was not determined
in the granulosa cells. While strong EGFR immunoreaction was observed in the
interstitial cells and oocyte cytoplasma, weak EGFR immunoreactions was
observed in theca cells of follicles.

As a
result, it was observed that the administered doses of TAM have not
significant influence on EGFR expression.

Anahtar Kelimeler

EGFR, Immunohistochemistry, Ovary, Tamoxifen

Effect of tamoxifen treatment on the epidermal growth factor receptor expression in the mouse ovarian tissue

Öz

The objective of
this study was to investigate the effect of Tamoxifen (TAM) treatment on
epidermal growth factor receptor (EGFR) expression in the pubertal mice ovary. In this study, 80 female mice (8 week-old) were used.
Animals divided four groups; non-injected (control A), injected with TAM’s
vehicle solution (control B). The mice in groups TAM 0.5 and TAM 1.5 were
treated with tamoxifen at a dose 0.5 and 1.5 mg/mouse/day respectively. TAM was
dissolved with 10% ethanol: 90% corn oil. Mice were
given daily subcutaneously injections for 5 days. Ovarian sections were
immunostained with EGFR antibody and triple staining for examine the general
structure. We observed that follicular atresia was increased, follicular cysts
were formed in stroma, and interstitial cells were increased with TAM dose
treatment. In the present study, there were no significant differences in the
EGFR expression in mouse ovary of all groups. EGFR expression was not determined
in the granulosa cells. While strong EGFR immunoreaction was observed in the
interstitial cells and oocyte cytoplasma, weak EGFR immunoreactions was
observed in theca cells of follicles.

As a
result, it was observed that the administered doses of TAM have not
significant influence on EGFR expression.

Anahtar Kelimeler

EGFR, Immunohistochemistry, Ovary, Tamoxifen

Kaynakça

• 1. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist, 4: 31-39, 2002.
• 2. Ashkenazi H, Cao X, Motola S, Popliker M, Conti M, Tsafriri A. Epidermal growth factor family members: endogenous mediators of the ovulatory response. Endocrinology, 146: 77-84, 2005.
• 3. Atalay G, Cardoso F, Awada A, Piccart MJ. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol, 14: 1346-1363, 2003.
• 4. Ayyagari RR, Khan-Dawood FS. Human corpus luteum: presence of epidermal growth factor receptors and its binding characteristics. Am J Obstet Gynecol, 150: 942-946, 1987.
• 5. Bernstein L, Deapen D, Cerhan JR. Tamoksifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst, 91: 1654–1662, 1999.
• 6. Blumenfeld Z, Dann E, Avivi R, Epelbaum R, Rowe JM. Fertility after treatment for hodgkin’s disease. Ann Oncol, 13: 138-147, 2002.
• 7. Clarke M, Cillins R, Davies C. Tamoksifen for early breast cancer: an overview of the randomized trials. Lancet, 351: 1451-1467, 1998.
• 8. Crossmonn GA. Modification of Mallory’s Connective Tissue stain with a discussion of the principles ınvolved. Anat Rec, 69(1): 33-38, 1937.
• 9. Das K, Stout LE, Hensleigh HC, Tagatz GE, Phipps WR, Leung BS. Direct positive effect of epidermal growth factor on the cytoplasmic maturation of mouse and human oocytes. Fertil Steril, 55: 1000–1004, 1991.
• 10. Dowsett M1, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL. Shak S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol, 28(11): 1829-1834, 2010.
• 11. Duncan MD, Korman LY, Bass BL. Epidermal growth factor primes intestinal epithelial cells for proliferative effect of insulin-like growth factor I. Dig Dis Sci, 39: 2197-201, 1994.
• 12. Ergin K, Gursoy E, Bağımoğlu KY, Baġaloğlu H, Seyrek K. Immunohistochemical detection of insulin-like growth factor-I, transforming growth factor-b2, basic fibroblast growth factor and epidermal growth factor-receptor expression in developing rat ovary. Cytokine, 43: 209-214, 2008.
• 13. Feng P, Knecht M, Cart K. Hormonal control of epidermal growth factor receptors by gonadotropins during granulosa cell differentiation. Endocrinology, 120: 1121-1128, 1987.
• 14. Fisher B, Constantino J, Redmond CK. Endometrial cancer in tamoksifen-treated breast cancer patients: Findings from The National Surgical Adjuvant Breast and Bowel Project (NSABP). J Natl Cancer Inst, 86, 527–537, 1994.
• 15. Fong SL, Lugtenburg PJ, Schipper I, Themmen APN, Jong FH, Sonneveld P. Anti-Müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod, 23: 674-678, 2008.
• 16. Fromowitz FB, Viola MV, Chao S, Oravez S, Mishriki Y, Finkel G, Grimson R, Lundy J, Ras 21 expression in the progression of breast cancer. Hum Pathol 18: 1268-1275, 1987.
• 17. Garnett, K, Wang J, Roy SK. Spatiotemporal expression of epidermal growth factor receptor messenger rna and protein in the hamster ovary: follicle stage-specific differential modulation by follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone. Biol Reprod, 67: 1593-1604, 2002.
• 18. Goldrisch A, Gelber RD. Castiglione M. for the international breast cancer study group. adjuvant therapy of breast cancer. Eur J Cancer, 27: 399-402, 1991.
• 19. Gorodeski GI, Beery R, Lunenfeld B, Geier A. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and post menopausal endometrium. Fertil Steril, 57: 320–327, 1992.
• 20. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancer. Semin Oncol, 29: 27–36, 2002.
• 21. Hudson LG, Zeineldin R, Silberberg M, Stack MS. Activated epidermal growth factor receptor in ovarian cancer. Cancer Treat Res, 149: 203-226, 2009.
• 22. Jolles CJ, Smotkin D, Ford KL, Jones K.P. Cystic ovarian necrosis complicating tamoxifen therapy for breast cancer in a premenopausal woman: a case report. J Reprod Med, 35: 299–300, 1990.
• 23. Jones PBC, Welsh TH, Jr Hsueh AJW. Regulation of ovarian progestin production by epidermal growth factor in cultured rat granulosa cells. J Biol Chem, 257: 11268, 1982.
• 24. Jordan V.C. Hoerner S. Tamoxifen and the human carcinoma 8S estrogen receptor. Eur J Cancer, 11: 205–206, 1975.
• 25. Jordan VC, O'Malley BW. Selective Estrogen-Receptor Modulators and antihormonal resistance in breast cancer. J Clin Oncol, 25: 5815-5824, 2007.
• 26. Knecht M, Catt KJ. Modulation of cAMP-mediated differentiation in ovarian granulosa cells by growth factor and platelet-derived growth factor. J Biol Chem, 258: 2789, 1983.
• 27. Lassus H, Sihto H, Leminen A. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med, 84(8): 671–681, 2006.
• 28. Liu JH, Baker J, Perkins A, Robertson E, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor (Igf-1) and Type I IGF receptor (Igf1r). Cell, 75: 59–72, 1993.
• 29. Lichtner RB. Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother, 57(10): 447-451, 2003.
• 30. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Enright E, Stecker K, Sgroi DC. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell, 5(6): 607–616, 2004.
• 31. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogenaction. Pharmacol Rev, 50(2): 151-196, 1998.
• 32. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update, 7: 535–543, 2001.
• 33. Moreno-Cuevas, J, Khan-Dawood FS. Epidermal growth factor receptors in rat ovarian tissue. Tissue & Cell, 29(1): 55-62,1997.
• 34. Nathan L, Chaudhuri G. Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol, 16: 309–314, 1998.
• 35. Onagbesan OM, Gullick W, Woolveridge I, Peddie MJ. Immunohistochemical localization of epidermal growth factor receptors, epidermal-growth-factor-like and transforming-growth-factor-a-like peptides in chicken ovarian follicles. J Reprod Fertil, 102: 147–153, 1994.
• 36. Qu J, Godin PA, Nisolle M, Donmez J. Distribution and epidermal growth factor receptor expression of primordial follicle in human ovarian tissue before and after cryopreservation. Hum Reprod, 15(2): 302-310, 2000.
• 37. Reeka N, Berg FD, Brucker C. Presence of transforming growth factor alpha and epidermal growth factor in human ovarian tissue and follicular fluid. Hum Reprod, 13:(8) 2199-2205, 1998.
• 38. Roy SK, Greenwald GS. Immunohistochemical localization of epidermal growth factor-like activity in the hamster ovary with a polyclonal antibody. Endocrinology, 126: 1309-1317, 1990.
• 39. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornader T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst, 87: 645-650, 1995.
• 40. Salomon DS, Brandt R, Ciardiello F. Epidermal growth factor-related peptides and their receptors in human malig- nancies. Crit Rev Oncol Hematol, 19: 183-232, 1995.41. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science, 295, 2465-2468, 2002.
• 42. Spinelli G, Bardozzi N, Citernessi A, Fontonarosa M, Curiel P. Endometrial carcinoma in tamoxifen treated cancer patients. J Chemother, 3: 267-270, 1991.
• 43. St. Arnaud R, Walker P, Kelley PA, Labrie E. Rat ovarian epidermal growth factor receptors: characterization and hormonal regulation. Mol Cell Endocrinol, 31: 43-56. 1983.
• 44. Stadlmann S, Gueth U, Reiser U. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Modern Pathology, 19(4): 607-610, 2006.
• 45. Stewart CJ. Expression of EGFr in normal ovary and in ovarian tumors. Int J Gynecol Pathol, 11: 266-272, 1992.
• 46. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: A review. J Clin Oncol, 9: 1283-1297, 1991.
• 47. Ting AY, Petroff BK. Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat. J Assist Reprod Genet, 27(11): 591-597, 2010.
• 48. Uberal, I, Kolar Z, Trojanec R, Berkovcova J, Hajduch M. The status and role of ErbB receptors in human cancer. Exp Mol Pathol, 84: 79-89, 2008.
• 49. Vlodavsky I, Brown KD, Gospodarowicz D. A comparison of the binding of epidermal growth factor to cultured granulosa and luteal cells. J Biol Chem, 253: 3744, 1978.
• 50. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer, 12: 553-563, 2002.